Kiniksa Pharmaceuticals International, plc Quarterly Depreciation in USD from Q2 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Kiniksa Pharmaceuticals International, plc quarterly/annual Depreciation history and growth rate from Q2 2017 to Q2 2024.
  • Kiniksa Pharmaceuticals International, plc Depreciation for the quarter ending June 30, 2024 was $119K, a 59.2% decline year-over-year.
  • Kiniksa Pharmaceuticals International, plc Depreciation for the twelve months ending June 30, 2024 was $801K, a 23.8% decline year-over-year.
  • Kiniksa Pharmaceuticals International, plc annual Depreciation for 2023 was $1.11M, a 5.94% decline from 2022.
  • Kiniksa Pharmaceuticals International, plc annual Depreciation for 2022 was $1.18M, a 19% decline from 2021.
  • Kiniksa Pharmaceuticals International, plc annual Depreciation for 2021 was $1.46M, a 39.5% decline from 2020.
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $801K $119K -$173K -59.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-25
Q1 2024 $974K $154K -$135K -46.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-04-25
Q4 2023 $1.11M $236K -$57K -19.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $1.17M $292K +$115K +65% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 $1.05M $292K -$58K -16.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-25
Q1 2023 $1.11M $289K -$70K -19.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-04-25
Q4 2022 $1.18M $293K -$83K -22.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $1.26M $177K -$196K -52.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $1.46M $350K -$66K -15.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-01
Q1 2022 $1.52M $359K +$69K +23.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $1.46M $376K -$191K -33.7% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $1.65M $373K -$276K -42.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $1.92M $416K -$179K -30.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $2.1M $290K -$304K -51.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $2.41M $567K +$1K +0.18% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-02
Q3 2020 $2.4M $649K +$126K +24.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $2.28M $595K +$87K +17.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $2.19M $594K +$123K +26.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $2.07M $566K +$312K +123% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 $1.76M $523K +$511K +4258% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $1.25M $508K +$496K +4133% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $749K $471K +$463K +5788% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-04
Q4 2018 $286K $254K Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 $12K +$4K +50% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $12K +$6K +100% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 $8K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q3 2017 $8K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 $6K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.